Core Viewpoint - ClearPoint Neuro, Inc. will release its financial results for the third quarter of 2024 on November 7, 2024, after market close, inviting investors and analysts to participate in a live broadcast and conference call [1][2] Company Overview - ClearPoint Neuro is a global device, cell, and gene therapy-enabling company that provides precise navigation to the brain and spine, offering both established clinical products and preclinical development services for controlled drug and device delivery [2] - The flagship product, the ClearPoint Neuro Navigation System, has received FDA clearance and is CE-marked, indicating its compliance with regulatory standards [2] - The company collaborates with healthcare and research centers across North America, Europe, Asia, and South America, and partners with innovative pharmaceutical and biotech companies, academic centers, and contract research organizations [2] - Thousands of procedures have been performed using the company's products, supported by a field-based clinical specialist team that provides services to customers and partners globally [2]
ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024